Posted by Michael Wonder on 12 Nov 2020
After NICE okay, Scots denied access to Vifor’s Veltassa
10 November 2020 - The SMC has ruled that there’s not enough evidence to support NHS funding of Vifor Pharma’s Veltassa for excess potassium in the blood (hyperkalaemia), even though patients in England can access the medicine.
It’s the second time that the SMC has rejected Veltassa (patiromer), having previously turned it down for hyperkalaemia in 2018.
